{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:58:14Z","timestamp":1790693894637,"version":"4.1.0"},"reference-count":56,"publisher":"Bioscientifica","issue":"9","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Resistance to endocrine therapy (ET) remains a major clinical challenge in the treatment of estrogen receptor-positive (ER+) breast cancer, underscoring the need for novel therapeutic targets. To identify genetic drivers of ET resistance, we conducted an in vivo genome-wide CRISPR-Cas9 screen in MCF7 cells implanted into ovariectomized nude mice under estrogen-deprived conditions. Despite the bottlenecks inherent to in vivo pooled screening, recurrent enrichment analysis identified NFKB1 as a candidate regulator of estrogen-independent tumor progression. Functional studies confirmed that NFKB1 deficiency enhanced tumorigenicity and conferred resistance to tamoxifen and fulvestrant both in vitro and in vivo. Mechanistically, transcriptomic and biochemical analyses revealed that NFKB1 deficiency activated canonical NF-\u03baB signaling, leading to inflammatory gene induction and enhanced ER signaling. Furthermore, pharmacologic inhibition of NF-\u03baB signaling restored ET sensitivity in NFKB1-deficient cells. Analysis of TCGA breast cancer datasets revealed reduced NFKB1 expression in luminal breast tumors, whereas expression of other NF-\u03baB family members was largely unchanged. Further analysis showed that low NFKB1 expression was associated with poorer clinical outcomes in patients with ER+ breast cancer. Collectively, these findings identify NFKB1 as a negative regulator of NF-\u03baB signaling and endocrine resistance in ER+ breast cancer and provide mechanistic evidence linking NF-\u03baB activation to ligand-independent ER signaling. Our results support further investigation of NFKB1 as a candidate biomarker and of NF-\u03baB pathway inhibition as a potential therapeutic strategy in endocrine therapy-resistant breast cancer. These findings also illustrate the utility of in vivo CRISPR screening for identifying candidate regulators of endocrine resistance in breast cancer.<\/jats:p>","DOI":"10.1530\/erc-25-0463","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:31:48Z","timestamp":1789381908000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["<i>In vivo<\/i>\n                    CRISPR screening links NFKB1 to endocrine resistance in ER+ breast cancer"],"prefix":"10.1530","volume":"33","author":[{"given":"Cancan","family":"Lyu","sequence":"first","affiliation":[{"name":"Department of Neuroscience and Pharmacology, University of Iowa 1 , , ,","place":["Iowa City, Iowa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel D","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Neuroscience and Pharmacology, University of Iowa 1 , , ,","place":["Iowa City, Iowa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Stamnes","sequence":"additional","affiliation":[{"name":"Department of Molecular Physiology and Biophysics, University of Iowa 2 , , ,","place":["Iowa City, Iowa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-7125","authenticated-orcid":true,"given":"Songhai","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neuroscience and Pharmacology, University of Iowa 1 , , ,","place":["Iowa City, Iowa, USA"]},{"name":"Holden Comprehensive Cancer Center, Carver College of Medicine, University of Iowa 3 , , ,","place":["Iowa City, Iowa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"2026092909591818900_bib1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.annonc.2024.10.824","article-title":"Estrogens and breast cancer","volume":"36","author":"Kim","year":"2025","journal-title":"Ann Oncol"},{"key":"2026092909591818900_bib2","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of clinical oncology guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026092909591818900_bib3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/978-3-031-70875-6_22","article-title":"Targeting oestrogen receptor signalling in breast cancer therapy","volume":"1464","author":"Howell","year":"2025","journal-title":"Adv Exp Med Biol"},{"key":"2026092909591818900_bib4","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3390\/cancers17101653","article-title":"Mechanisms and therapeutic strategies for endocrine resistance in breast cancer: a comprehensive review and meta-analysis","volume":"17","author":"Khan","year":"2025","journal-title":"Cancers"},{"key":"2026092909591818900_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41571-024-00935-6","article-title":"Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer","volume":"21","author":"Lloyd","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026092909591818900_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.seminoncol.2011.01.002","article-title":"CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine","volume":"38","author":"de Souza","year":"2011","journal-title":"Semin Oncol"},{"key":"2026092909591818900_bib7","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae051","article-title":"Estrogen receptor alpha mutations, truncations, heterodimers, and therapies","volume":"165","author":"Hancock","year":"2024","journal-title":"Endocrinology"},{"key":"2026092909591818900_bib8","doi-asserted-by":"crossref","first-page":"R369","DOI":"10.1530\/ERC-19-0087","article-title":"The NF-KB pathway and endocrine therapy resistance in breast cancer","volume":"26","author":"Khongthong","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2026092909591818900_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrc3950","article-title":"Applications of the CRISPR-Cas9 system in cancer biology","volume":"15","author":"Sanchez-Rivera","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2026092909591818900_bib10","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.7150\/thno.71144","article-title":"CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives","volume":"12","author":"Chan","year":"2022","journal-title":"Theranostics"},{"key":"2026092909591818900_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk7786","article-title":"Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers","volume":"17","author":"Cai","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026092909591818900_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add3685","article-title":"CRISPR-Cas9 screen reveals a role of purine synthesis for estrogen receptor alpha activity and tamoxifen resistance of breast cancer cells","volume":"9","author":"Hany","year":"2023","journal-title":"Sci Adv"},{"key":"2026092909591818900_bib13","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.1073\/pnas.1722617115","article-title":"Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy","volume":"115","author":"Xiao","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092909591818900_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1261283","article-title":"The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026092909591818900_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.trecan.2018.03.002","article-title":"Cancer CRISPR screens in vivo","volume":"4","author":"Chow","year":"2018","journal-title":"Trends Cancer"},{"key":"2026092909591818900_bib16","article-title":"The ubiquitin-proteasome system and activation of NF-kappaB: involvement of the ubiquitin ligase KPC1 in p105 processing and tumor suppression","volume":"2","author":"Kravtsova-Ivantsiv","year":"2015","journal-title":"Mol Cell Oncol"},{"key":"2026092909591818900_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/cells7090133","article-title":"NFKB1 and cancer: friend or foe?","volume":"7","author":"Concetti","year":"2018","journal-title":"Cells"},{"key":"2026092909591818900_bib18","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/1541-7786.MCR-19-1082","article-title":"The NF-kappaB pathway promotes tamoxifen tolerance and disease recurrence in estrogen receptor-positive breast cancers","volume":"18","author":"Kastrati","year":"2020","journal-title":"Mol Cancer Res"},{"key":"2026092909591818900_bib19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"Sanjana","year":"2014","journal-title":"Nat Methods"},{"key":"2026092909591818900_bib20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41388-024-03224-9","article-title":"Unveiling RACK1: a key regulator of the PI3K\/AKT pathway in prostate cancer development","volume":"44","author":"Lyu","year":"2025","journal-title":"Oncogene"},{"key":"2026092909591818900_bib21","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10985549.2023.2285833","article-title":"Active Galpha(i\/o) mutants accelerate breast tumor metastasis via the c-Src pathway","volume":"43","author":"Lyu","year":"2023","journal-title":"Mol Cell Biol"},{"key":"2026092909591818900_bib22","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.cell.2015.02.038","article-title":"Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis","volume":"160","author":"Chen","year":"2015","journal-title":"Cell"},{"key":"2026092909591818900_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"key":"2026092909591818900_bib24","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2009-10-3-r25","article-title":"Ultrafast and memory-efficient alignment of short DNA sequences to the human genome","volume":"10","author":"Langmead","year":"2009","journal-title":"Genome Biol"},{"key":"2026092909591818900_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"2026092909591818900_bib26","article-title":"Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors","volume":"5","author":"Gyorffy","year":"2024","journal-title":"Innovation"},{"key":"2026092909591818900_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.150532","article-title":"Targeting Gi\/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy","volume":"6","author":"Lyu","year":"2021","journal-title":"JCI Insight"},{"key":"2026092909591818900_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmgh.2025.101666","article-title":"A dual-compartment scaffolding role for receptor for activate C kinase 1 in hepatic glucagon signaling and gluconeogenesis","volume":"20","author":"Lyu","year":"2026","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026092909591818900_bib29","doi-asserted-by":"crossref","first-page":"djv073","DOI":"10.1093\/jnci\/djv073","article-title":"MCF-7 cells--changing the course of breast cancer research and care for 45 years","volume":"107","author":"Lee","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2026092909591818900_bib30","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/s41417-023-00664-5","article-title":"Clonal dynamics limits detection of selection in tumour xenograft CRISPR\/Cas9 screens","volume":"30","author":"Lee","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"2026092909591818900_bib31","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41587-024-02512-9","article-title":"CRISPR-StAR enables high-resolution genetic screening in complex in vivo models","volume":"43","author":"Uijttewaal","year":"2025","journal-title":"Nat Biotechnol"},{"key":"2026092909591818900_bib32","doi-asserted-by":"crossref","first-page":"24162","DOI":"10.1074\/jbc.M201576200","article-title":"The death domain of NF-\u03baB1 p105 is essential for signal-induced p105 proteolysis","volume":"277","author":"Beinke","year":"2002","journal-title":"J Biol Chem"},{"key":"2026092909591818900_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/ni.1685","article-title":"Proteolysis of NF-\u03baB1 p105 is essential for T cell antigen receptor-induced proliferation","volume":"10","author":"Sriskantharajah","year":"2009","journal-title":"Nat Immunol"},{"key":"2026092909591818900_bib34","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/cancers13071511","article-title":"Targeting the IL-6\/STAT3 signalling Cascade to reverse tamoxifen resistance in estrogen receptor positive breast cancer","volume":"13","author":"Tsoi","year":"2021","journal-title":"Cancers"},{"key":"2026092909591818900_bib35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2009.10.014","article-title":"An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation","volume":"139","author":"Iliopoulos","year":"2009","journal-title":"Cell"},{"key":"2026092909591818900_bib36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13058-022-01585-1","article-title":"Identification of a novel ER-NFkB-driven stem-like cell population associated with relapse of ER+ breast tumors","volume":"24","author":"Semina","year":"2022","journal-title":"Breast Cancer Res"},{"key":"2026092909591818900_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-012-2053-1","article-title":"NFkappaB signaling is important for growth of antiestrogen resistant breast cancer cells","volume":"135","author":"Yde","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2026092909591818900_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jhep.2010.03.025","article-title":"The NF-kappaB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes","volume":"53","author":"Elsharkawy","year":"2010","journal-title":"J Hepatol"},{"key":"2026092909591818900_bib39","doi-asserted-by":"crossref","first-page":"8460","DOI":"10.1074\/jbc.M312398200","article-title":"Bcl-3 and NFkappaB p50-p50 homodimers act as transcriptional repressors in tolerant CD4+ T cells","volume":"279","author":"Grundstrom","year":"2004","journal-title":"J Biol Chem"},{"key":"2026092909591818900_bib40","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cell.2015.03.001","article-title":"KPC1-mediated ubiquitination and proteasomal processing of NF-kappaB1 p105 to p50 restricts tumor growth","volume":"161","author":"Kravtsova-Ivantsiv","year":"2015","journal-title":"Cell"},{"key":"2026092909591818900_bib41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.molcel.2009.04.033","article-title":"The Nfkb1 and Nfkb2 proteins p105 and p100 function as the core of high-molecular-weight heterogeneous complexes","volume":"34","author":"Savinova","year":"2009","journal-title":"Mol Cell"},{"key":"2026092909591818900_bib42","doi-asserted-by":"crossref","first-page":"6818","DOI":"10.1038\/ncomms7818","article-title":"NFkappaB1 is a suppressor of neutrophil-driven hepatocellular carcinoma","volume":"6","author":"Wilson","year":"2015","journal-title":"Nat Commun"},{"key":"2026092909591818900_bib43","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.immuni.2018.03.003","article-title":"Loss of NF-kappaB1 causes gastric cancer with aberrant inflammation and expression of immune checkpoint regulators in a STAT-1-dependent manner","volume":"48","author":"O'Reilly","year":"2018","journal-title":"Immunity"},{"key":"2026092909591818900_bib44","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1038\/onc.2014.211","article-title":"Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor","volume":"34","author":"Voce","year":"2015","journal-title":"Oncogene"},{"key":"2026092909591818900_bib45","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1053\/j.gastro.2020.06.039","article-title":"Loss of NFKB1 results in expression of tumor necrosis factor and activation of signal transducer and activator of transcription 1 to promote gastric tumorigenesis in mice","volume":"159","author":"Low","year":"2020","journal-title":"Gastroenterology"},{"key":"2026092909591818900_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1618193","article-title":"Identification and validation of genes related to stem cells and telomere maintenance mechanisms as biomarkers for breast cancer","volume":"16","author":"Zhen","year":"2025","journal-title":"Front Immunol"},{"key":"2026092909591818900_bib47","doi-asserted-by":"crossref","first-page":"8918","DOI":"10.1158\/0008-5472.CAN-09-2608","article-title":"Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer","volume":"69","author":"Frasor","year":"2009","journal-title":"Cancer Res"},{"key":"2026092909591818900_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.molcel.2005.03.006","article-title":"Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation","volume":"18","author":"Park","year":"2005","journal-title":"Mol Cell"},{"key":"2026092909591818900_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40170-021-00252-x","article-title":"Tumor suppressor SMAR1 regulates PKM alternative splicing by HDAC6-mediated deacetylation of PTBP1","volume":"9","author":"Choksi","year":"2021","journal-title":"Cancer Metab"},{"key":"2026092909591818900_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbcan.2010.08.003","article-title":"Gene regulation by SMAR1: role in cellular homeostasis and cancer","volume":"1815","author":"Malonia","year":"2011","journal-title":"Biochim Et Biophys Acta Rev Cancer"},{"key":"2026092909591818900_bib51","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1371\/journal.pone.0000660","article-title":"p53 target gene SMAR1 is dysregulated in breast cancer: its role in cancer cell migration and invasion","volume":"2","author":"Singh","year":"2007","journal-title":"PLoS One"},{"key":"2026092909591818900_bib52","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.4161\/15384101.2014.954454","article-title":"Loss of circadian clock gene expression is associated with tumor progression in breast cancer","volume":"13","author":"Cadenas","year":"2014","journal-title":"Cell Cycle"},{"key":"2026092909591818900_bib53","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1158\/1541-7786.MCR-07-2094","article-title":"The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response","volume":"6","author":"Hoffman","year":"2008","journal-title":"Mol Cancer Res"},{"key":"2026092909591818900_bib54","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.devcel.2017.10.027","article-title":"Tumor-suppressor inactivation of GDF11 occurs by precursor sequestration in triple-negative breast cancer","volume":"43","author":"Bajikar","year":"2017","journal-title":"Dev Cell"},{"key":"2026092909591818900_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1476-4598-8-73","article-title":"The proprotein convertase PC5\/6 is protective against intestinal tumorigenesis: in vivo mouse model","volume":"8","author":"Sun","year":"2009","journal-title":"Mol Cancer"},{"key":"2026092909591818900_bib56","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12935-021-02379-9","article-title":"Cervical cancer-derived exosomal miR-663b promotes angiogenesis by inhibiting vinculin expression in vascular endothelial cells","volume":"21","author":"You","year":"2021","journal-title":"Cancer Cell Int"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0463\/525274\/erc-25-0463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0463\/525274\/erc-25-0463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:59:37Z","timestamp":1790690377000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/9\/e250463\/78204\/In-vivo-CRISPR-screening-links-NFKB1-to-endocrine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0463","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"e250463"}}